Header

Pediatric Leukemia Clinical Trials

Category:Pediatric
Status:Active

Displaying all 13 trials

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

This partially randomized phase III clinical trial is studying different combinations of risk-adapted chemotherapy regimens and their side effects and comparing how well they work in treating young...

Diagnosis: Pediatric Oncology, Pediatric Leukemia

Phase: 3

Protocol Number: 12-211

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

This randomized phase III trial is studying how well combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia that is likely to come back or sprea...

Diagnosis: Pediatric Leukemia

Phase: 3

Protocol Number: 13-486

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

This randomized phase III trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia ...

Diagnosis: Pediatric Lymphoma, Pediatric Leukemia

Phase: 3

Protocol Number: 15-032

Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

This randomized phase II trial studies how well donor umbilical cord blood transplant with or without ex-vivo expanded cord blood progenitor cells works in treating patients with acute myeloid leuk...

Diagnosis: Pediatric Hematopoietic Stem Cell Transplant (HSCT), Pediatric Leukemia

Phase: 2

Protocol Number: 13-042

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell ly...

Diagnosis: Pediatric Leukemia

Phase: 1 / 2

Protocol Number: 15-226

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

This research study involves participants who have acute lymphoblastic or acute myelogenous leukemia that has relapsed or has become resistant (or refractory) to standard therapies. This research s...

Diagnosis: Pediatric Leukemia

Phase: 1

Protocol Number: 13-563

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

The purpose of this study is to test the safety of giving the patient special cells made from their own blood called "Modified T-cells". The goal is to find a safe dose of modified T-cell...

Diagnosis: Pediatric Leukemia

Phase: 1

Protocol Number: 13-526

Matched Targeted Therapy For High-Risk Leukemias

This research study is seeking to gain new knowledge about Recurrent, Refractory, or High Risk Leukemias in children and young adults. This study is evaluating the use of specialized testing called...

Diagnosis: Pediatric Leukemia

Phase: N/A

Protocol Number: 15-384

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

This phase III trial studies tretinoin and arsenic trioxide in treating patients with newly diagnosed acute promyelocytic leukemia. Standard treatment for acute promyelocytic leukemia involves high...

Diagnosis: Pediatric Leukemia, Pediatric Oncology

Phase:

Protocol Number: 15-719

Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

This study will examine the appropriate dose and side effects of dasatinib, when it is given with the standard of care chemotherapy for children and adolescents with Acute Myeloid Leukemia (AML).

Diagnosis: Pediatric Leukemia

Phase:

Protocol Number: 15-581

Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

This phase I/II trial studies the side effects and best dose of liposomal cytarabine-daunorubicin CPX-351 (CPX-351) when given with fludarabine phosphate, cytarabine, and filgrastim and to see how ...

Diagnosis: Pediatric Leukemia

Phase:

Protocol Number: 16-717

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow...

Diagnosis: Pediatric Leukemia

Phase:

Protocol Number: 16-001

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laborato...

Diagnosis: Pediatric Lymphoma, Pediatric Leukemia

Phase:

Protocol Number: 16-725

'